Curative study on Recombinant Bovine Basic Fibroblast Growth Factor Eye-Gel combined with Diquafosol Sodium Eye Drops in treatment of dry eye after cataract surgery
Objective To explore the clinical curative effect of Recombinant Bovine Basic Fibroblast Growth Factor Eye-Gel combined with Diquafosol Sodium Eye Drops in treatment of dry eye after cataract surgery.Methods Patients(60 cases)with dry eye after cataract surgery in Cangzhou Eye Hospital from July 2022 to July 2023 were randomly divided into control(30 cases)and treatment(30 cases)group.Patients in the control group were administered with Diquafosol Sodium Eye Drops,1—2 drops/time,four times daily.Patients in the treatment group were administered with Recombinant Bovine Basic Fibroblast Growth Factor Eye-Gel on the basis of the control group,twice daily.Patients in two groups were treated for 7 d.After treatment,the clinical evaluations were evaluated,the symptom relief time,the scores FL and OSDI,and the levels of serum IL-1β,TNF-α,MDA and SOD in two groups before and after treatment were compared.Results After treatment,the clinical effective rate of the treatment group was 96.67%,which was significantly higher than that of the control group(73.33%,P<0.05).After treatment,the time of symptom improvement in the treatment group was significantly earlier than that in the control group(P<0.05).After treatment,the scores of FL and OSDI in two groups were significantly lower than those before treatment(P<0.05),especially in the treatment group(P<0.05).After treatment,the serum levels of IL-1β,TNF-α and MDA in two groups decreased significantly,while the level of SOD was significantly increased(P<0.05),and the level of serum factors in the treatment group was significantly better than that in the control group(P<0.05).Conclusion The combination of Recombinant Bovine Basic Fibroblast Growth Factor Eye-Gel and Diquafosol Sodium Eye Drops can effectively restore clinical symptoms and improve the state of ocular inflammatory reaction.
NETL
NSTL
万方数据
